- Home
- NETD vs ESPR Comparison
NETD vs ESPR Comparison
Compare NETD & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NETD
- ESPR
- Stock Information
- Founded
- NETD 2023
- ESPR 2008
- Country
- NETD United States
- ESPR United States
- Employees
- NETD N/A
- ESPR N/A
- Industry
- NETD
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- NETD
- ESPR Health Care
- Exchange
- NETD Nasdaq
- ESPR Nasdaq
- Market Cap
- NETD 412.5M
- ESPR 410.2M
- IPO Year
- NETD 2023
- ESPR 2013
- Fundamental
- Price
- NETD $10.82
- ESPR $2.21
- Analyst Decision
- NETD
- ESPR Buy
- Analyst Count
- NETD 0
- ESPR 5
- Target Price
- NETD N/A
- ESPR $5.13
- AVG Volume (30 Days)
- NETD 57.0K
- ESPR 4.6M
- Earning Date
- NETD 01-01-0001
- ESPR 02-25-2025
- Dividend Yield
- NETD N/A
- ESPR N/A
- EPS Growth
- NETD N/A
- ESPR N/A
- EPS
- NETD 0.45
- ESPR N/A
- Revenue
- NETD N/A
- ESPR $295,451,000.00
- Revenue This Year
- NETD N/A
- ESPR $186.88
- Revenue Next Year
- NETD N/A
- ESPR $22.46
- P/E Ratio
- NETD $24.07
- ESPR N/A
- Revenue Growth
- NETD N/A
- ESPR 187.12
- 52 Week Low
- NETD $10.38
- ESPR $1.58
- 52 Week High
- NETD $10.83
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- NETD 62.37
- ESPR 44.94
- Support Level
- NETD $10.81
- ESPR $2.05
- Resistance Level
- NETD $10.83
- ESPR $2.40
- Average True Range (ATR)
- NETD 0.02
- ESPR 0.14
- MACD
- NETD -0.00
- ESPR 0.01
- Stochastic Oscillator
- NETD 70.00
- ESPR 45.71
About NETD Nabors Energy Transition Corp. II
Nabors Energy Transition Corp II is a blank check company.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.